Neurocrine Biosciences, Inc.
Key Metrics
- Previous Close
- $165.92
- 52-Week Range
- $122.14 – $186.12
- Market Cap
- $16.48B
- P/E (TTM)
- 24.16
- EPS (TTM)
- 6.74
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 4.25
- PEG Ratio
- 0.33
- Return on Equity
- 20.41%
- Return on Assets
- 12.45%
- Gross Margin
- 64.67%
- Operating Margin
- 26.62%
- Profit Margin
- 18.98%
- Current Ratio
- 2.04
- Debt/Equity
- 0.12
- Total Debt
- $451.80M
- Free Cash Flow
- $1.02B
- Revenue Growth
- 41.20%
- Earnings Growth
- -3.90%
- Enterprise Value
- $16.20B
Market Snapshot
About
Neurocrine Biosciences, Inc. discovers and develops treatments for neurological, neuroendocrine, and neuropsychiatric disorders. The company markets INGREZZA for tardive dyskinesia and develops a pipeline targeting conditions like schizophrenia, endometriosis, and congenital adrenal hyperplasia. Neurocrine focuses on diseases with significant unmet medical needs where neurological pathways play a central role.